The epidemiology of COVID-19 is rapidly evolving and a number of companies have begun to invest in this space. The absence of proven therapeutic options and the lack of a vaccine to protect against infection has led to a race to develop effective interventions. A range of players – from pharma and biotech firms to academic institutions and government agencies – have thrown their hats in the ring.
Scope
Global epidemiology metrics and trends
Snapshot of epidemiological trends to date in the top three most-affected countries
An overview of the pipeline for antivirals and vaccines
Summary of available efficacy data
An assessment of the clinical trials landscape by phase, sponsor type, geography, and other key attributes
Highlights in deal-making trends, particularly public-private partnerships
Spotlight on social media coverage
Reasons to buy
Global epidemiology metrics and trends
Snapshot of epidemiological trends to date in the top three most-affected countries
An overview of the pipeline for antivirals and vaccines
Summary of available efficacy data
An assessment of the clinical trials landscape by phase, sponsor type, geography, and other key attributes
Highlights in deal-making trends, particularly public-private partnerships
Spotlight on social media coverage
'
Table of Contents
1 Executive Summary
1.1 Report Scope
1.2 Navigate the COVID-19 Outbreak with GlobalData Pharma’s COVID-19 Dashboard
1.3 Monitor the COVID-19 Outbreak with GlobalData Epidemiology Indicators
2 Epidemiology
2.1 Epidemiology: Snapshot as of March 25, 2020
2.2 Epidemiology: Disease Trajectory as of March 25, 2020
2.3 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in China as of March 25, 2020
2.4 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in Italy as of March 25, 2020
2.5 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in the US as of March 25, 2020
2.6 Epidemiology Forecast: United States
3 Pipeline Overview
3.1 Pipeline Therapeutics: Breakdown by Phase
3.2 Pipeline Therapeutics: Breakdown by Molecule Type
3.3 Pipeline Therapeutics: Breakdown by Type of Developer
3.4 Pipeline Therapeutics: Clinical-Stage Candidates (Phase I – III)
3.5 Pipeline Therapeutics: Preclinical-Stage Candidates
3.6 Pipeline Therapeutics: Currently Available Data
3.7 Pipeline Vaccines: Breakdown by Phase
3.8 Pipeline Vaccines: Breakdown by Developer Type
3.9 Pipeline Vaccines: Clinical and Preclinical-Stage Candidates
Pipeline Overview
4.1 Pipeline Therapeutics: Breakdown by Phase
4.2 Pipeline Therapeutics: Breakdown by Molecule Type
4.3 Pipeline Therapeutics: Breakdown by Type of Developer
4.4 Pipeline Therapeutics: Clinical-Stage Candidates (Phase I – III)
4.5 Pipeline Therapeutics: Preclinical-Stage Candidates
4.6 Pipeline Therapeutics: Currently Available Data
4.7 Pipeline Vaccines: Breakdown by Phase
4.8 Pipeline Vaccines: Breakdown by Developer Type
4.9 Pipeline Vaccines: Clinical and Preclinical-Stage Candidates
Clinical Trials
5.1 Clinical Trials: Breakdown by Phase
5.2 Clinical Trials for Therapeutics and Vaccines
5.3 Clinical Trials: Overview by Region
5.4 Clinical Trials for Therapeutics: Leading Sponsors
5.5 Clinical Trials: Leading Industry Sponsors
5.6 Trends in Trial Design
Deal-making Trends
6.1 Deal-making Trends
Social Media Trends
7.1 Key Twitter Chatter
7.2 Top Trending Tweets include #Covid19 #Coronavirus #Patients #Flattenthecurve
Key Findings
8.1 Key Findings
Appendix
9.1 Sources
9.2 Methodology
9.3 About the Authors
About GlobalData
10.1 Contact Us
